AIDS Funding Increased for Fiscal '97

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 11
Volume 5
Issue 11

WASHINGTON-Federal AIDS programs faired well in the budget bill passed by Congress and signed by President Clinton, which included increased funding in fiscal year 1997 for research, prevention, care, and drug assistance.

WASHINGTON—Federal AIDS programs faired well in the budget bill passed by Congress and signed by President Clinton, which included increased funding in fiscal year 1997 for research, prevention, care, and drug assistance.

The legislation provided the Department of Health and Human Services, which funds the vast majority of AIDS projects, with $3.213 billion for its AIDS programs outside of Medicare and Medicaid. This represents a 12.4% increase over the $2.856 billion provided in fiscal 1996, according to the White House Office of National AIDS Policy.

The legislation upped funding for programs that help HIV patients purchase drugs to $167 million, an increase of 221%; increased AIDS research funding at NIH to $1.5 billion, a 6.7% increase; and provided $617 million for AIDS prevention programs, a 6% increase.

Recent Videos
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
2 experts are featured in this series.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
A collaboration between the Connecticut Departments of Health and Corrections and the COPPER Center aimed to improve outcomes among incarcerated patients.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
4 experts are featured in this series.
Related Content